BCMA-Targeted Therapies in Multiple Myeloma: What the Pharmacist Needs...

201 Waterfront Street,National Harbor MD 20745

13 October, 2022

Description

Activity ChairRyan Haumschild, PharmD, MS, MBA Director of Pharmacy Emory Healthcare Winship Cancer Institute Atlanta, GA FacultyCraig Freyer, PharmD, BCOP Clinical Pharmacy Specialist – Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy Penn Medicine at The Pavilion of Hospital of the University of Pennsylvania Philadelphia, PA OverviewAlthough the median overall survival rate for patients with multiple myeloma (MM) has nearly doubled during the last 2 decades, MM remains incurable, and a majority of patients develop relapsed disease. The prognosis is poor among these patients, with a median overall survival of just over 1 year after 3 lines of therapy. Although improvements in diagnosis, risk stratification, and treatment continue—with multiple agents now available from various drug classes—additional novel agents with improved efficacy and safety are still needed, particularly in the relapsed or refractory setting. Several therapies have recently been approved that target B-cell maturation antigen (BCMA), a transmembrane protein expressed by malignant plasma cells that is involved in plasma and B-cell survival, B-cell maturation and growth, and activation of regulatory T cells. In this activity, expert clinicians will review the current treatment guidelines and the most recent clinical data supporting the use of BCMA-targeted for relapsed/refractory MM, define the disease and clinical characteristics of patients for whom BCMA-targeted therapy is appropriate, and describe the optimal multidisciplinary care coordination strategies for the management of treatment-emergent adverse events in patients receiving BCMA-targeted therapies. Agenda6:00 PM Registration and Dinner 6:30 PM Introduction and Pretest 6:35 PM Therapeutic Options for Relapsed/Refractory Multiple Myeloma 6:50 PM Targeting BCMA in Relapsed/Refractory Disease 7:05 PM Safety Considerations Associated With BCMA-Targeted Therapies 7:25 PM Clinical Cases 7:45 PM Posttest and Question & Answer 8:00 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Outline current guideline recommendations for the treatment of relapsed/refractory MM.Review the patient, disease, and treatment characteristics that may make patients likely to benefit from BCMA-targeted therapies.Assess the latest clinical efficacy data and safety profiles for recently approved BCMA-targeted therapies for patients with relapsed/refractory MM.Define multidisciplinary care coordination strategies for the recognition and management of adverse events in patients receiving BCMA-targeted therapies.Target AudienceThe intended audience for this activity is managed care pharmacists, oncology pharmacists, and other health care professionals involved in the management of patients with MM.